Inhibitor Therap Financials
This page shows Inhibitor Therap (INTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Recurring cash burn is shrinking the asset base faster than costs are falling, leaving a liquid but undercapitalized company.
FY2025 shows the key split: short-term liquidity still looks workable, with a current ratio of 3.2x and cash of$2.4M . But negative equity of about-$1.3M shows that repeated losses have already exhausted the capital cushion, creating a clear gap between bill-paying capacity and long-term balance-sheet support.
The operating model has been remarkably steady in the wrong direction: operating cash outflow stayed near
Loss absorption, not heavy dilution, appears to be the main balance-sheet driver: equity went from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Inhibitor Therap's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Inhibitor Therap has a moderate D/E ratio of -0.03. This balance of debt and equity financing earns a leverage score of 64/100.
Inhibitor Therap's current ratio of 3.19 indicates adequate short-term liquidity, earning a score of 62/100. The company can meet its near-term obligations, though with limited headroom.
Inhibitor Therap passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Inhibitor Therap generates $0.98 in operating cash flow (-$3.2M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Inhibitor Therap reported -$3.3M in net income in fiscal year 2025. This represents an increase of 1.2% from the prior year.
Inhibitor Therap earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Cash & Balance Sheet
Inhibitor Therap held $2.4M in cash against $37K in long-term debt as of fiscal year 2025.
Inhibitor Therap had 173M shares outstanding in fiscal year 2025. This represents an increase of 0.1% from the prior year.
Margins & Returns
Capital Allocation
Inhibitor Therap invested $1.7M in research and development in fiscal year 2025. This represents a decrease of 3.5% from the prior year.
INTI Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $341K | N/A | $378K+16.0% | $326K+37.9% | $236K | N/A | $370K+54.2% | $240K |
| SG&A Expenses | $355K | N/A | $363K-1.8% | $370K-15.6% | $438K | N/A | $444K+28.4% | $345K |
| Operating Income | -$696K | N/A | -$741K-6.5% | -$696K-3.1% | -$675K | N/A | -$813K-39.0% | -$585K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$686K | N/A | -$712K-7.9% | -$660K-4.3% | -$633K | N/A | -$731K-45.7% | -$502K |
| EPS (Diluted) | $0.00 | N/A | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 |
INTI Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4M-42.9% | $2.5M-19.9% | $3.1M-19.8% | $3.9M-13.3% | $4.5M-20.9% | $5.7M-11.7% | $6.5M-10.1% | $7.2M |
| Current Assets | $1.4M-43.8% | $2.4M-20.1% | $3.1M-20.0% | $3.8M-13.4% | $4.4M-22.4% | $5.7M-11.7% | $6.5M-10.1% | $7.2M |
| Cash & Equivalents | $1.3M-45.7% | $2.4M-20.2% | $3.0M-20.4% | $3.7M-13.5% | $4.3M-22.9% | $5.6M-12.1% | $6.4M-10.1% | $7.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.4M-10.3% | $3.8M+21.4% | $3.1M-1.9% | $3.2M+1.2% | $3.2M-15.0% | $3.7M+21.8% | $3.0M+0.3% | $3.0M |
| Current Liabilities | $382K-50.1% | $766K+775.5% | $88K-37.5% | $140K+47.8% | $95K-86.7% | $710K+1492.5% | $45K+25.4% | $36K |
| Long-Term Debt | $29K-20.4% | $37K-16.5% | $44K-15.1% | $52K-10.8% | $58K | N/A | N/A | N/A |
| Total Equity | -$2.0M-53.1% | -$1.3M-37514.2% | $3K-99.5% | $716K-47.1% | $1.4M-31.9% | $2.0M-41.7% | $3.4M-17.7% | $4.1M |
| Retained Earnings | -$56.1M-1.2% | -$55.4M-2.4% | -$54.1M-1.3% | -$53.4M-1.3% | -$52.8M-1.2% | -$52.1M-2.8% | -$50.7M-1.5% | -$50.0M |
INTI Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M-80.4% | -$601K+21.0% | -$761K-30.4% | -$584K+54.6% | -$1.3M-66.6% | -$771K-7.1% | -$720K-23.6% | -$583K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
INTI Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | -20625.1%-20532.9pp | -92.2%-45.4pp | -46.8% | N/A | -21.5%-9.3pp | -12.1% |
| Return on Assets | -47.9% | N/A | -22.7%-5.8pp | -16.9%-2.8pp | -14.1% | N/A | -11.3%-4.3pp | -7.0% |
| Current Ratio | 3.60+0.4 | 3.19-31.8 | 35.00+7.6 | 27.36-19.3 | 46.68+38.7 | 8.03-136.8 | 144.78-57.1 | 201.91 |
| Debt-to-Equity | -0.01+0.0 | -0.03-12.8 | 12.79+12.7 | 0.07+0.0 | 0.04-1.8 | 1.87+1.0 | 0.89+0.2 | 0.73 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
Is Inhibitor Therap profitable?
No, Inhibitor Therap (INTI) reported a net income of -$3.3M in fiscal year 2025.
How much debt does Inhibitor Therap have?
As of fiscal year 2025, Inhibitor Therap (INTI) had $2.4M in cash and equivalents against $37K in long-term debt.
What is Inhibitor Therap's operating cash flow?
Inhibitor Therap (INTI) generated -$3.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Inhibitor Therap's total assets?
Inhibitor Therap (INTI) had $2.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Inhibitor Therap spend on research and development?
Inhibitor Therap (INTI) invested $1.7M in research and development during fiscal year 2025.
What is Inhibitor Therap's current ratio?
Inhibitor Therap (INTI) had a current ratio of 3.19 as of fiscal year 2025, which is generally considered healthy.
What is Inhibitor Therap's debt-to-equity ratio?
Inhibitor Therap (INTI) had a debt-to-equity ratio of -0.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Inhibitor Therap's return on assets (ROA)?
Inhibitor Therap (INTI) had a return on assets of -131.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Inhibitor Therap's cash runway?
Based on fiscal year 2025 data, Inhibitor Therap (INTI) had $2.4M in cash against an annual operating cash burn of $3.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Inhibitor Therap's debt-to-equity ratio negative or unusual?
Inhibitor Therap (INTI) has negative shareholder equity of -$1.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Inhibitor Therap's Piotroski F-Score?
Inhibitor Therap (INTI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Inhibitor Therap's earnings high quality?
Inhibitor Therap (INTI) has an earnings quality ratio of 0.98x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Inhibitor Therap?
Inhibitor Therap (INTI) scores 21 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.